ovarian cancer raloxifene aspirin multidose initial series, then 1 dose at 2-6 months colorectal cancer Hepatitis C ≥ 20% 40-70 y.o., ASCVD ≥ 10%, low bleeding risk ≥ 200 mg/dL cervical cancer q1y 50 y.o. Gail model 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor pneumococcal Timed up and go test q2y women age 55- 64 y.o. q5y statin dementia ≥ 126 mg/dL Hepatitis B q1y mammogram 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors tobacco use 40-59 y.o., ASCVD ≥ 10%, low bleeding risk Tyrer- Cuzick model insufficient evidence for screening 3% 2 doses, 2-6 months apart overweight / obesity < 60 y.o. 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor depression Fracture Risk Assessment Tool PREVENT equation diabetes 52 y.o. tamoxifen q15y ≥ 140 mg/dL aromatase inhibitors 65 y.o. ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors HIV ≥ 6.5% community- dwelling, postmenopausal women hormone therapy lung cancer cardiovascular disease hypertension 60 y.o. anxiety q1-2y mammogram based on life expectancy / health status ≥ 100 mg/dL 40 y.o. ≥ 5.7% 1 dose; 2 doses (2-6 months apart) if immunocomp herpes zoster breast cancer dyslipidemia 75 y.o. q3y ≤ q2y ovarian cancer raloxifene aspirin multidose initial series, then 1 dose at 2-6 months colorectal cancer Hepatitis C ≥ 20% 40-70 y.o., ASCVD ≥ 10%, low bleeding risk ≥ 200 mg/dL cervical cancer q1y 50 y.o. Gail model 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor pneumococcal Timed up and go test q2y women age 55- 64 y.o. q5y statin dementia ≥ 126 mg/dL Hepatitis B q1y mammogram 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors tobacco use 40-59 y.o., ASCVD ≥ 10%, low bleeding risk Tyrer- Cuzick model insufficient evidence for screening 3% 2 doses, 2-6 months apart overweight / obesity < 60 y.o. 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor depression Fracture Risk Assessment Tool PREVENT equation diabetes 52 y.o. tamoxifen q15y ≥ 140 mg/dL aromatase inhibitors 65 y.o. ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors HIV ≥ 6.5% community- dwelling, postmenopausal women hormone therapy lung cancer cardiovascular disease hypertension 60 y.o. anxiety q1-2y mammogram based on life expectancy / health status ≥ 100 mg/dL 40 y.o. ≥ 5.7% 1 dose; 2 doses (2-6 months apart) if immunocomp herpes zoster breast cancer dyslipidemia 75 y.o. q3y ≤ q2y
(Print)
ovarian cancer
raloxifene
aspirin
multidose initial series, then 1 dose at 2-6 months
colorectal cancer
Hepatitis C
≥ 20%
40-70 y.o., ASCVD ≥ 10%, low bleeding risk
≥ 200 mg/dL
cervical cancer
q1y
50 y.o.
Gail model
40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
pneumococcal
Timed up and go test
q2y
women age 55-64 y.o.
q5y
statin
dementia
≥ 126 mg/dL
Hepatitis B
q1y mammogram
40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
tobacco use
40-59 y.o., ASCVD ≥ 10%, low bleeding risk
Tyrer-Cuzick model
insufficient evidence for screening
3%
2 doses, 2-6 months apart
overweight / obesity
< 60 y.o.
40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
depression
Fracture Risk Assessment Tool
PREVENT equation
diabetes
52 y.o.
tamoxifen
q15y
≥ 140 mg/dL
aromatase inhibitors
65 y.o.
≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
HIV
≥ 6.5%
community-dwelling, postmenopausal women
hormone therapy
lung cancer
cardiovascular disease
hypertension
60 y.o.
anxiety
q1-2y mammogram based on life expectancy / health status
≥ 100 mg/dL
40 y.o.
≥ 5.7%
1 dose; 2 doses (2-6 months apart) if immunocomp
herpes zoster
breast cancer
dyslipidemia
75 y.o.
q3y
≤ q2y
